After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, GILD falls under the Healthcare sector while operating within the Drug Manufacturers – General industry segment. The current market capitalization of Gilead Sciences, Inc. is $87.16B. A total of 4.54 million shares were traded on the day, compared to an average of 7.65M shares.
In the most recent transaction, Parsey Merdad sold 2,000 shares of GILD for 68.63 per share on Jul 01 ’24. After the transaction, the Chief Medical Officer now owns 96,380 company shares. In a previous transaction on Apr 02 ’24, GILEAD SCIENCES, INC. bought 485,250 shares at 0.76 per share. GILD shares that 10% Owner owns now total 7,345,473.
Among the insiders who sold shares, Parsey Merdad disposed of 2,000 shares on Apr 01 ’24 at a per-share price of $72.96. This resulted in the Chief Medical Officer holding 96,304 shares of GILD after the transaction. In another insider transaction, Parsey Merdad sold 8,230 shares at $72.74 per share on Feb 29 ’24. Company shares held by the Chief Medical Officer now total 92,706.
Dividend
Investors prefer companies that pay dividends because dividends generate immediate cash flow and indicate a positive outlook. Gilead Sciences, Inc. pays an annual dividend of $3.04, resulting in a dividend yield of 4.35%, and it has a price to earnings (P/E) ratio of 195.04. GILD’s most recent ex-dividend date was 6/14/2024 when it declared a $0.77 quarterly dividend that was paid in cash on 6/27/2024. Previously, the company paid the dividend on 3/28/2024 with an ex-dividend date of 3/14/2024. The GILD stock dividend was $0.77 per share in cash.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, GILD has a high of $87.86 and a low of $62.07.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. GILD’s latest balance sheet shows that the firm has $6.52B in Cash & Short Term Investments as of fiscal 2021. There were $26.70B in debt and $11.61B in liabilities at the time. Its Book Value Per Share was $14.08, while its Total Shareholder’s Equity was $21.06B.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GILD is Buy with a score of 3.92.
